In April 2016, a group of researchers, clinicians, and cannabis advocates gathered in a lecture hall at Harvard Medical School for something that had never happened before: a rigorous, science-first medical cannabis conference hosted at one of the world’s most prestigious academic institutions. The keynote speaker was Dr. Raphael Mechoulam, the Israeli chemist who first isolated THC in 1964 and who many call the father of cannabis research. He was there to receive a lifetime achievement award and to signal that the scientific study of cannabis had arrived.
A decade later, that event has grown into one of the most respected gatherings in the global cannabis space. The CannMed 26 Innovation and Collaboration Summit will take place June 15–18 at the Hyatt Regency Lake Tahoe—and its organizers are marking the milestone with a “Decade of Discovery” celebration that reflects on how far the field, and the conference, have come.
A Conference Born from a Family’s Fight
The story of CannMed begins not in a boardroom, but in a hospital. Kevin McKernan, the founder and chief scientific officer of Medicinal Genomics Corporation, had spent years developing next-generation sequencing technologies to help clinicians diagnose rare genetic disorders. But his work shifted to something more personal when his father was diagnosed with stage-4 prostate cancer.
With guidance from pioneering cannabis clinicians, including Dr. Raphael Mechoulam, Dr. Bonni Goldstein, Dr. Dustin Sulak, Dr. Debra Kimless, and Mara Gordon, the McKernan family used cannabis therapies to help maximize their father’s quality of life.
“The day we got him on cannabis, he felt like a king,” said Brendan McKernan, CEO, Medicinal Genomics. “His bone pain went away. His nausea went away. He started gaining weight again for the first time. And he outlived his diagnosis for four years.”
While the results astonished the skeptical doctors and nurses overseeing his care, Kevin and his brother Brendan recognized a critical gap between cannabis science and clinical practice. CannMed was their answer. A conference built on a simple premise: cannabis is medicine, and advancing it demands the same rigor applied to any other therapeutic discipline.
The Harvard Beginning
Hosting the inaugural conference at Harvard Medical School was both a bold statement and a practical one. In 2016, cannabis research was still deeply stigmatized, and its status as a Schedule I controlled substance greatly restricted the ability of American scientists to study it. Many skeptics thought the term “medical cannabis” was just a clever ploy by potheads to find a path to legalize their drug of choice.
“When I think of conferences that are at the forefront of cannabis science, medicine, and technology, CannMed is the first one that comes to mind,” said Michael Straumietis, CEO & Founder, Advanced Nutrients. “This event aligns with my values and mission to make cannabis an acceptable and everyday part of healing humanity through innovation.”
The Science at the Center
“The world is now flooded with cannabis conference options, but the one to be at has always been, and will likely always be, CannMed,” said Dr. Staci Gruber, McLean Hospital Brain Imaging Center, Harvard Medical School. “It is a standalone, truly scientific conference where data is presented from all sides.”
Over the years, CannMed presentations have addressed the clinical potential of cannabinoids in epilepsy, cancer, chronic pain, PTSD, and autism; breakthroughs in cultivation techniques and pathogen management; advances in laboratory testing and safety standards; and the complex pharmacology of minor cannabinoids like CBG.
CannMed 26 at Lake Tahoe
CannMed 26 will feature curated presentations, interactive panels, professional workshops, and immersive networking. The “Decade of Discovery” anniversary dinner will honor ten years of progress, connection, and the community that made it possible.
For the McKernan brothers, the milestone is personal. What began as a response to their father’s illness has become a global community of scientists, clinicians, and advocates united by a shared conviction: that cannabis is medicine, and that proving it requires innovation and collaboration.
